Literature DB >> 6339081

Target cell specificity of human natural killer (NK) cells. I. Development of an NK-resistant subline of K562.

S L MacDougall, C Shustik, A K Sullivan.   

Abstract

By depletion of effector-target conjugates and cloning, a variant of the human leukemic line K562 that is partially resistant to lysis by natural killer (NK) cells when tested under conditions of culture and assay identical to that of the parent has been derived. Its karyotype shows markers similar to the original K562. The resistant phenotype remains stable after over 1 year of continuous passage and persists in multiple replicate subclones. However, it can be killed to a degree equal to the parent by antibody-activated complement, antibody-dependent cellular mechanisms, and by effector cells activated by staphylococcal protein A. These observations and experiments on cold target competition suggest that on its surface there is a significantly decreased, absent, or blocked effective target structure for a major population of unstimulated peripheral blood NK cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6339081     DOI: 10.1016/0008-8749(83)90346-5

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  4 in total

1.  Infection of a human leukemia K-562 cell line with Semliki Forest virus.

Authors:  D D King; B Brady; D Dodd; C J Wust; A Brown
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

2.  Increased fucosylation of glycolipids in a human leukaemia cell line (K562-Clone I) with decreased sensitivity to NK-mediated lysis.

Authors:  S L MacDougall; G A Schwarting; D Parkinson; A K Sullivan
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

3.  Membrane markers, target cell specificity, and sensitivity to biological response modifiers distinguish human natural cytotoxic from human natural killer cells.

Authors:  M Rola-Pleszczynski; H Lieu; A K Sullivan; M Girard
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

4.  Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.

Authors:  Lingyan Wang; Yue Zhang; Eden Anderson; Adam Lamble; Rimas J Orentas
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.